Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 19;21(10):3583. doi: 10.3390/ijms21103583

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The co-treatment of YC-1, an HIF-1α inhibitor, with cilastatin worsened renal function and tubular necrosis in mouse kidney with IR injury. (A) Serum creatinine levels were significantly increased at 24 h after IR injury and decreased in mouse kidney with IR injury with cilastatin pretreatment. Co-treatment with cilastatin and YC-1 exacerbated renal function in mouse kidney with IR injury. (B) The representative staining with hematoxylin and eosin showed a decreased tubular necrosis (arrows) in the cilastatin-treated mouse kidney with IR injury, and aggravated tubular necrosis in mouse kidney with IR injury co-treated with cilastatin and YC-1 (original magnification, × 200). The data are presented as means ± SEM. * p < 0.05 vs. sham; ^† p < 0.05 vs. IR group; ^‡ p < 0.05 vs. IR + Cila group.